Study of Recombinant Human Insulin-Like Growth Factor I in Patients With Severe Insulin Resistance
Status:
Completed
Trial end date:
2000-09-01
Target enrollment:
Participant gender:
Summary
OBJECTIVES: I. Determine the efficacy and toxic effects of recombinant human insulin-like
growth factor I (rhIGF-I) on carbohydrate tolerance, insulin action, insulin secretion,
hyperandrogenism, and hyperlipidemia in patients with severe insulin resistance who have
failed other therapies.
II. Determine the dose and time response of rhIGF-I on carbohydrate homeostasis and secondary
abnormalities in this patient population.
III. Determine the effect of rhIGF-I on insulin clearance, the regulation of insulin-like
growth factor binding protein 1, the regulation of sex hormone binding globulin, and
hypothalamic pituitary gonadal axis in this patient population.
Phase:
N/A
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center
Treatments:
Complement Factor I Insulin Insulin, Globin Zinc Mitogens